Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
Experts
ScoPo’s powerplays: Searching for gems as healthcare sector languishes
Health & Biotech
Healthkick Podcast: Neuren is cashed up, confident and charging into a phase 3 trial
Experts
ScoPo’s powerplays: ‘It’s a new dawn… get in front of these extraordinary opportunities’
Health & Biotech
Antisense Therapeutics’ FDA ruling could be worth ‘hundreds of millions’
Health & Biotech
World-renown cancer institute to investigate Kazia Therapeutics drug
Health & Biotech
Incannex persists with CBD, hydroxychloroquine COVID drug
Health & Biotech
Health: Immutep has dosed the last patient in one of its cancer studies
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
The healthcare winners and losers after COVID-19, and what comes next
Experts
Scopo’s health powerplays: Clinical trials are back
Experts
Scopo’s health powerplays: Markets be crazy, buy the dip
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: Even bacteria fighter Next Science is feeling the coronavirus pinch
Health & Biotech
Health: Neuren’s mice are happily burying marbles after PMS neurotherapy
Health & Biotech
Health: Neuren gets extra FDA push for its treatment for rare Rett disease
Health & Biotech